Clinical trials: Active Population
Healthy
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo.
- Trial name
- NCT02183155
- Testing
- Meloxicam - low, Meloxicam - medium, Meloxicam - high
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of…
- Trial name
- NCT06733402
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Schizophrenia
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia…
- Trial name
- NCT01009047
- Testing
- Paliperidone extended release (ER), Aripiprazole
- Where
- 41 sites in United States, India and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
- Trial name
- ADMYRA (NCT02744755)
- Testing
- Adalimumab - GP2017, Adalimumab - US licensed Humira
- Where
- 83 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Sandoz
Gastric Ulcer
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
- Trial name
- NCT07730138
- Testing
- DWP14012 40mg (Fexuprazan), Lansoprazole 30mg
- Where
- 2 sites in Indonesia, South Korea
- Volunteers
- 384 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Healthy Adults
Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
This study is a single-center, randomized, open-label, active and placebo-controlled, parallel-group, conducted in healthy male volunteers who have been shown to be extensive metabolizers of dextromethorphan.
- Trial name
- NCT01367535
- Testing
- SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Menorrhagia
Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.
- Trial name
- NCT00360490
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 165 people
- Sponsor
- Bayer
Non-Cystic Fibrosis Bronchiectasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.
- Trial name
- NCT06981091
- Testing
- XH-S004 20 mg, XH-S004 40 mg
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Multiple Sclerosis
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
- Trial name
- NCT02576717
- Testing
- RPC1063
- Where
- 175 sites in United States, Belarus and 24 more
- Volunteers
- 2,494 people
- Sponsor
- Celgene
Low Back Pain
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks).
- Trial name
- TANGO (NCT02528253)
- Testing
- Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
- Where
- 262 sites in United States, Canada and 7 more
- Volunteers
- 1,832 people
- Sponsor
- Pfizer
Erosive Esophagitis (EE)
Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis
This is a multi-center, randomized, double-blind, parallel-group, active controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50 mg comparing with esomeprazole 40 mg after the treatment of erosive…
- Trial name
- NCT03615677
- Testing
- LXI-15028 50mg, Esomeprazole 40mg
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Parenteral Nutrition
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 versus NTCB-C in patients who require parenteral nutrition
- Trial name
- NCT06625957
- Testing
- NTCB02-1, NTCB-C
- Where
- 5 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Yuhan Corporation
Femoral Arterial Stenosis, Stenosis of Popliteal Arteries
LEVANT Japan Clinical Trial
To demonstrate the safety and efficacy of MD02-LDCB for treatment of stenosis or occlusion of the femoral and popliteal arteries in the Japanese population.
- Conditions
- Femoral Arterial Stenosis, Stenosis of Popliteal Arteries, Femoral Artery Occlusion, Occlusion of Popliteal Arteries
- Trial name
- NCT01816412
- Testing
- MD02-LDCB Paclitaxel coated balloon catheter, Standard Uncoated Balloon Angioplasty Catheter
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- C. R. Bard
Diabetes Mellitus
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in…
- Trial name
- NCT02059564
- Testing
- HM11260C, Victoza
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.
- Trial name
- NCT02558400
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
- Where
- United States
- Volunteers
- 718 people
- Sponsor
- Aerie Pharmaceuticals
Rheumatoid Arthritis
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA…
- Trial name
- NCT02996500
- Testing
- PF-06650833, Tofacitinib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Dyslipidemias
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or…
- Trial name
- NCT02977065
- Testing
- Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.